Albert Bourla, Pfizer CEO (Michel Euler/AP Images, Pool)
May 31, 2023 05:58 PM EDTUpdated June 1, 11:02 AM
Pharma
FDA+

FDA ap­proves Pfiz­er’s RSV shot for old­er adults, tee­ing up a com­pet­i­tive $17B vac­cine mar­ket

Andrew Dunn

Senior Biopharma Correspondent

The FDA ap­proved Pfiz­er’s RSV vac­cine called Abrys­vo for old­er adults on Wednes­day, plac­ing an­oth­er Big Phar­ma on­to the com­mer­cial stage ahead of the next …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times